These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29923294)

  • 1. Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
    Andersen G; Meiffren G; Lamers D; DeVries JH; Ranson A; Seroussi C; Alluis B; Gaudier M; Soula O; Heise T
    Diabetes Obes Metab; 2018 Nov; 20(11):2627-2632. PubMed ID: 29923294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.
    McVey E; Hirsch L; Sutter DE; Kapitza C; Dellweg S; Clair J; Rebrin K; Judge K; Pettis RJ
    J Diabetes Sci Technol; 2012 Jul; 6(4):743-54. PubMed ID: 22920798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
    Heise T; Meiffren G; Alluis B; Seroussi C; Ranson A; Arrubla J; Correia J; Gaudier M; Soula O; Soula R; DeVries JH; Klein O; Bode B
    Diabetes Obes Metab; 2019 Apr; 21(4):1066-1070. PubMed ID: 30565407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients.
    Schernthaner G; Wein W; Sandholzer K; Equiluz-Bruck S; Bates PC; Birkett MA
    Diabetes Care; 1998 Apr; 21(4):570-3. PubMed ID: 9571344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
    Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes.
    Meiffren G; Herbrand T; Anastassiadis E; Klein O; DeVries JH; Heise T; Alluis B; Mégret C; Gaudier M; Soula O; Plum-Mörschel L
    Diabetes Obes Metab; 2019 Jul; 21(7):1570-1575. PubMed ID: 30828929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
    Leohr J; Kazda C; Liu R; Reddy S; Dellva MA; Matzopoulos M; Loh MT; Hardy T; Klein O; Kapitza C
    Diabetes Obes Metab; 2022 Feb; 24(2):187-195. PubMed ID: 34605142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
    Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
    Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.
    Malone JK; Woodworth JR; Arora V; Yang H; Campaigne BN; Hallé JP; Yale JF; Grossman LD
    Clin Ther; 2000 Feb; 22(2):222-30. PubMed ID: 10743981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
    Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
    Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.
    Kazda C; Leohr J; Liu R; Reddy S; Dellva MA; Loh MT; Hardy T; Plum-Mörschel L
    Diabetes Obes Metab; 2022 Feb; 24(2):196-203. PubMed ID: 34595812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postprandial Glucose Excursions with Ultra-Rapid Insulin Analogs in Hybrid Closed-Loop Therapy for Adults with Type 1 Diabetes.
    Haliloglu B; Boughton CK; Lakshman R; Ware J; Nwokolo M; Thabit H; Mader JK; Bally L; Leelarathna L; Wilinska ME; Allen JM; Hartnell S; Evans ML; Hovorka R
    Diabetes Technol Ther; 2024 Jul; 26(7):449-456. PubMed ID: 38315506
    [No Abstract]   [Full Text] [Related]  

  • 15. Ultra rapid lispro improves postprandial glucose control versus lispro in combination with basal insulin: a study based on CGM in type 2 diabetes in China.
    Yuan L; Luo Y; Luo Y; Ding B; Zhang P; Ma J; Wu J
    Front Endocrinol (Lausanne); 2024; 15():1364585. PubMed ID: 38774225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus.
    Aronson R; Biester T; Leohr J; Pollom R; Linnebjerg H; LaBell ES; Zhang Q; Coutant DE; Danne T
    Diabetes Obes Metab; 2023 Jul; 25(7):1964-1972. PubMed ID: 36974352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes.
    Deeb LC; Holcombe JH; Brunelle R; Zalani S; Brink S; Jenner M; Kitson H; Perlman K; Spencer M
    Pediatrics; 2001 Nov; 108(5):1175-9. PubMed ID: 11694699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes.
    Rami B; Schober E
    Eur J Pediatr; 1997 Nov; 156(11):838-40. PubMed ID: 9392394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.